Intuitive Surgical Tops Q1 Estimates on Robot Demand

INTUITIVE SURGICAL INC reported first-quarter financial results on Tuesday that exceeded Wall Street expectations for both profit and revenue. The company’s performance was bolstered by a surge in demand for its minimally invasive surgical robots, which are increasingly utilized in complex medical procedures worldwide. The medical device manufacturer reported adjusted earnings of $2.50 per share for the quarter ending March 31, significantly outperforming the $2.10 per share anticipated by analysts. Total revenue for the period reached $2.77 billion, surpassing the consensus estimate of $2.62 billion. This growth reflects a consistent uptake of the company's flagship da Vinci systems as hospitals work through a backlog of surgical procedures and broaden patient access to advanced robotic care. Global procedure volume for the da Vinci systems grew by approximately 16% compared to the same period last year. These robots are employed across a variety of medical fields, including weight-loss surgeries, kidney procedures, and gastric bypasses. Following the strong quarterly performance, the company raised its full-year 2026 outlook, now projecting worldwide procedure growth between 13.5% and 15.5%, up from the previous range of 13% to 15%. Despite its market-leading position, the company faces new competition from MEDTRONIC PLC, whose Hugo robotic system received regulatory clearance late last year. This approval represents the first major competitive challenge to the da Vinci platform in the robotic-assisted surgery sector. Looking ahead, the company also adjusted its financial guidance for 2026. It now expects an adjusted gross profit margin between 67.5% and 68.5% of revenue, a slight increase from the earlier projection of 67% to 68%. Management noted that this updated range accounts for an estimated 1% impact on revenue resulting from international tariffs.